The Role of Immunotherapies in Late-Relapse Multiple Myeloma
Released On
March 31, 2025
Expires On
March 31, 2026
Media Type
Internet
Completion Time
60 minutes
Specialty
Hematology-Oncology
Topic(s)
Multiple Myeloma, Oncology
Educational Provider
This activity is provided by USF Health in partnership with Paradigm Medical Communications, LLC, Moffitt Cancer Center, and Multiple Myeloma Research Foundation.
Supporter Acknowledgement
This activity is funded by independent medical education grants from AbbVie, Janssen Scientific Affairs, LLC and Legend Biotech.
Credit Available
- Physicians - 1.0 AMA PRA Category 1 Credit™
- Nurse Practitioners - may claim a maximum of 1.0 Category 1 credit
- Physician Assistants - may claim a maximum of 1.0 Category 1 credit
- Nurses - 1.0 contact hour; 1.0 ANCC pharmacotherapeutic contact hour
- Pharmacists - 1 contact hour (0.01 CEU)
Target Audience
This activity has been designed to address the educational needs of hematologists/oncologists, medical oncologists, hematologists, pharmacists, nurses, nurse practitioners, PAs, residents, and fellows. It may also benefit other healthcare providers, including primary care physicians who manage patients with multiple myeloma (MM).
Program Overview
Despite the availability of many therapeutic options to treat MM, the disease usually progresses, and patients ultimately become refractory to specific agents or drug classes. Treatment selection and sequencing can be extremely challenging for clinicians. Fortunately, newer approaches to the treatment of relapsed/refractory MM (RRMM) have been developed, particularly with the advent of approved and upcoming chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies. This discussion will highlight the emerging and available agents that are critical to the evolving therapeutic landscape of MM.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Identify patients with RRMM who would be candidates for CAR T-cell therapy based on the latest clinical trial data for efficacy and safety
- Incorporate bispecific antibodies into the treatment of RRMM based on clinical trial data for efficacy and safety
- Discuss strategies to mitigate current disparities in MM when managing patients with the disease
Faculty
Rachid Baz, MD – Chairperson
Myeloma Section Head
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Moffitt Cancer Center
Tampa, FL
Melissa Alsina, MD
Head, Myeloma Section
Bone Marrow Transplant and Cellular Immunotherapy Program
Moffitt Cancer Center
Tampa, FL
Peter Voorhees, MD
Professor of Medicine
Chief, Plasma Cell Disorders Division
Levine Cancer Institute
Atrium Health
Charlotte, NC
Accreditations
Physicians
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Advanced Practice Providers
Physician Assistants may claim a maximum of 1.0 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.
The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 Credit™ by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.
Nurses
USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1 contact hour may be earned by learners who successfully complete this continuing nursing education activity. USF Health, the accredited provider, acknowledges Paradigm Medical Communications, LLC as the partner in the planning and execution of this CNE activity.
This activity is awarded 1.0 ANCC pharmacotherapeutic contact hour.
Pharmacists
USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 1 contact hour (0.01 CEU). Universal program number is as follows: 0230-9999-25-005-H01-P.
Date of original release: March 31, 2025. Date credit expires: March 31, 2026.
Disclosure of Relevant Financial Relationships
USF Health adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below.
FacultyRachid Baz, MD
Advisory board or panel fees: Janssen; Pfizer
Grants/research support: AbbVie; Bristol Myers Squibb; Janssen; Karyopharm; Regeneron
Melissa Alsina, MD
Advisory board or panel fees: Bristol Myers Squibb; Janssen; Sanofi
Grants/research support: Bristol Myers Squibb; Janssen; Sanofi
Peter Voorhees, MD
Advisory board or panel fees: AbbVie; Ascentage Pharma (relationship ended); AstraZeneca (relationship ended); Bristol Myers Squibb; GSK (relationship ended); Janssen; Pfizer (relationship ended); Regeneron; Sanofi (relationship ended)
Content Reviewers
Alicia Canalejo, APRN has no financial interests/relationships or affiliations in relation to this activity.
Christy Thai, PharmD, BCPS has no financial interests/relationships or affiliations in relation to this activity.
Multiple Myeloma Research Foundation Reviewers
Christopher Peña, PhD has no financial interests/relationships or affiliations in relation to this activity.
Anne Quinn Young, MPH has no financial interests/relationships or affiliations in relation to this activity.
Staff
USF Health Office of Continuing Professional Development and Paradigm Medical
Communications, LLC staff have no relevant financial interests/relationships or affiliations in relation to this activity.
Instructions for Participation
To receive a certificate of participation, participants must:
- Follow instructions to register or log in with your professional information and complete the pretest
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
A certificate of participation will be available for download/printing immediately following your successful completion of the posttest and evaluation.
For questions regarding CME credit, please contact [email protected].
There are no fees for participating in this activity.
Hardware/Software Requirements
This accredited CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader.
Technical Support
If you have any technical problems or playback issues, please email [email protected].
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.
USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center, and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CE to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.
The information provided by this CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
Disclaimer
This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, USF Health and Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As ACCME-accredited providers, USF Health and Paradigm Medical Communications, LLC must ensure that their activities include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC and USF Health.
Terms of Use and Privacy policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, USF Health and Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by USF Health and Paradigm Medical Communications, LLC. USF Health and Paradigm Medical Communications, LLC accept no liability for the content referenced in this activity.
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Information
If you have any questions or comments, please email us at [email protected].
© 2025 USF Health and Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of USF Health and Paradigm Medical Communications, LLC.